Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 2 | 50.7% | +14.6% |
| SAJJADI, FEREYDOUN GHOTB | 1 | 42.0% | +47.8% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.3% | +35.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18952618 | USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS | SAJJADI, FEREYDOUN GHOTB | 22d overdue |
| 18837546 | STABLE PLINABULIN FORMULATIONS AND METHODS OF THEIR PREPARATION AND USE | GODDARD, LAURA B | 7d |
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | GODDARD, LAURA B | 9d |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 26d |
| 18671711 | PLINABULIN COMPOSITIONS | KIFLE, BRUCK | 34d |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1699 | 1 |
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952618 | USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS | SAJJADI, FEREYDOUN GHOTB | 1699 | §103 | Final Rejection | 22d overdue | Pending | Nov 19, 2024 |
| 18837546 | STABLE PLINABULIN FORMULATIONS AND METHODS OF THEIR PREPARATION AND USE | GODDARD, LAURA B | 1642 | §103 | Non-Final OA | 7d | Pending | Aug 09, 2024 |
| 18671711 | PLINABULIN COMPOSITIONS | KIFLE, BRUCK | 1624 | Other | Non-Final OA | 34d | Pending | May 22, 2024 |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 1627 | Other | Non-Final OA | 26d | Pending | Oct 09, 2023 |
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | GODDARD, LAURA B | 1642 | Other | Non-Final OA | 9d | Pending | Nov 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial